New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 30, 2014
07:08 EDTINSYInsys backs Q2 revenue view of over $52M, consensus $52.77M
Insys Therapeutics reaffirmed its revenue guidance for Q2 ended June 30. Revenue from sales of Subsys is expected to exceed $52M for the quarter, as compared with $18.5M during 2Q13.
News For INSY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 1, 2016
08:14 EDTINSYInsys Therapeutics longer term outlook stable, says RBC Capital
After surveying 40 doctors, including nine who prescribed large amounts of Insys' Subsys, RBC Capital says that payor pushback on the drug is "limited," while 95% of all the doctors surveyed and 89% of the high prescribers "intend to write as many or more Subsys prescriptions this year" as last year. The firm thinks the stock's valuation is attractive following its 61% pullback since July. It trimmed its price target on the stock to $44 from $49 but keeps an Outperform rating. .
January 25, 2016
12:57 EDTINSYInsys Therapeutics: Recent media reports' account of practices 'misleading'
Subscribe for More Information
10:27 EDTINSYOptions with increasing implied volatility: CLDX INSY SNDK
Subscribe for More Information
10:01 EDTINSYInsys finding 'new ways to mislead insurance companies,' SIRF says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use